Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
SSY Group ( (HK:2005) ) has shared an update.
SSY Group Limited has received approval from China’s National Medical Products Administration for the production and registration of two key pharmaceutical products: Composite Potassium Hydrogen Phosphate Injection and Vortioxetine Hydrobromide Tablets. These approvals, marking significant milestones for the company, enhance its product portfolio in treating hypophosphatemia, aiding parenteral nutrition, and addressing depression in adults, potentially bolstering its market presence and stakeholder confidence.
More about SSY Group
SSY Group Limited operates in the pharmaceutical industry, focusing on the development and production of chemical drugs. Its primary products include compound preparations and bulk drugs targeting various medical needs, such as parenteral nutrition and depression treatment. The company is positioned to serve both adult and child patients, enhancing its market focus on essential medical therapies.
YTD Price Performance: -5.31%
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $1.2B
For detailed information about 2005 stock, go to TipRanks’ Stock Analysis page.
